sulpiride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sulpiride derivatives 2537 15676-16-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulpiride
  • sulpirid
  • sulpitil
  • sulpyrid
  • sursumid
A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
  • Molecular weight: 341.43
  • Formula: C15H23N3O4S
  • CLOGP: 1.11
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 101.73
  • ALOGS: -2.80
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.80 g O
0.80 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.28 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 133.89 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.94 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1972 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Torsade de pointes 152.36 105.06 26 195 2220 2355644
Electrocardiogram QT prolonged 137.23 105.06 29 192 7785 2350079
Parkinsonism 126.72 105.06 21 200 1484 2356380
Ventricular fibrillation 125.48 105.06 22 199 2179 2355685

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 125.79 49.60 24 142 3124 1743491
Parkinsonism 70.52 49.60 13 153 1356 1745259
Poisoning deliberate 56.39 49.60 10 156 832 1745783
Abdominal pain upper 52.49 49.60 15 151 10986 1735629

Pharmacologic Action:

SourceCodeDescription
ATC N05AL01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Benzamides
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:48561 dopaminergic antagonist
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.47 acidic
pKa2 12.66 acidic
pKa3 8.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.12 CHEMBL IUPHAR
Carbonic anhydrase 2 Enzyme IC50 7.40 WOMBAT-PK
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.76 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8.41 CHEMBL
D(4) dopamine receptor GPCR Ki 5.68 CHEMBL
D(3) dopamine receptor GPCR Ki 8.10 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.97 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.44 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.51 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5.92 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.74 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 9.10 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.12 DRUG MATRIX
Dopamine receptor GPCR Ki 5.80 CHEMBL
Alpha carbonic anhydrase Unclassified Ki 6.37 CHEMBL
Astrosclerin-3 Unclassified Ki 6.42 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 5.64 CHEMBL
Carbonic anhydrase Unclassified Ki 6.38 CHEMBL
Delta carbonic anhydrase Unclassified Ki 6.59 CHEMBL
Carbonic anhydrase Enzyme Ki 6.91 CHEMBL
D(2) dopamine receptor GPCR IC50 6.70 CHEMBL
D(2) dopamine receptor GPCR Kd 8.82 CHEMBL
Carbonic anhydrase Enzyme Ki 6.75 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.14 CHEMBL
Carbonic anhydrase Enzyme Ki 7.40 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.58 CHEMBL
Carbonic anhydrase Unclassified Ki 7.53 CHEMBL
Carbonic anhydrase Enzyme Ki 6.95 CHEMBL

External reference:

IDSource
N0000166882 NUI
C0038803 UMLSCUI
D01226 KEGG_DRUG
7MNE9M8287 UNII
2359 INN_ID
321506004 SNOMEDCT_US
10239 RXNORM
395891007 SNOMEDCT_US
003764 NDDF
CHEMBL26 ChEMBL_ID
DB00391 DRUGBANK_ID
CHEBI:32168 CHEBI
D013469 MESH_DESCRIPTOR_UI
5355 PUBCHEM_CID
5501 IUPHAR_LIGAND_ID

Pharmaceutical products:

None